Biopsy targeting gliomas: Do functional imaging techniques identify similar target areas?

Investigative Radiology

Volumn 45, Issue 12, 2010, Pages 755-768

  Weber, Marc André ^a,b   Henze, Marcus ^b   Tüttenberg, Jochen ^c   Stieltjes, Bram ^a   Meissner, Marco ^a   Zimmer, Fabian ^a   Burkholder, Iris ^a   Kroll, Alexander ^a   Combs, Stephanie E ^d   Vogt Schaden, Marlies ^d   Giesel, Frederik L ^a,b   Zoubaa, Saida ^e   Haberkorn, Uwe ^b   Kauczor, Hans Ulrich ^b   Essig, Marco ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Biopsy planning; Glioma; Magnetic resonance imaging; Magnetic resonance spectroscopy; Positron emission tomography

Indexed keywords

3' FLUOROTHYMIDINE F 18; CHOLINE; CREATINE; FLUORODEOXYGLUCOSE F 18; GADOBENATE DIMEGLUMINE; GERMANIUM; N ACETYLASPARTIC ACID; SODIUM 23;

ADULT; AGED; ARTERIAL SPIN LABELING; ARTICLE; BRAIN BIOPSY; BRAIN BLOOD FLOW; BRAIN BLOOD VOLUME; BRAIN METABOLISM; BRAIN TUMOR; CANCER GRADING; CLINICAL PROTOCOL; CONTRAST ENHANCEMENT; DIAGNOSTIC TEST ACCURACY STUDY; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; DYNAMIC CONTRAST ENHANCED NUCLEAR MAGNETIC RESONANCE IMAGING; DYNAMIC SUSCEPTIBILITY WEIGHTED PERFUSION NUCLEAR MAGNETIC RESONANCE IMAGING; ECHO PLANAR IMAGING; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GLIOMA; HISTOLOGY; HUMAN; IMAGING SYSTEM; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MICROCIRCULATION; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PICTURE ARCHIVING AND COMMUNICATION SYSTEM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; SINGLE DRUG DOSE; WHOLE BODY MRI; WHOLE BODY PET; WHOLE BODY SCANNER;

EID: 78650677333     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0b013e3181ec9db0     Document Type: Article

References (57)

1. Henze M, Mohammed A, Schlemmer HP, et al. PET and SPECT for detection of tumor progression in irradiated low-grade astrocytoma: a receiver-operating- characteristic analysis. J Nucl Med. 2004;45:579-586.
2. Jacobs AH, Kracht LW, Gossmann A, et al. Imaging in neurooncology. NeuroRx. 2005;2:333-347.
3. Henson JW, Gaviani P, Gonzalez RG. MRI in treatment of adult gliomas. Lancet Oncol. 2005;6:167-175.
4. Weber MA, Giesel FL, Stieltjes B. MRI for identification of progression in brain tumors: from morphology to function. Expert Rev Neurother. 2008;8: 1507-1525.
5. Ouwerkerk R, Bleich KB, Gillen JS, et al. Tissue sodium concentration in human brain tumors as measured with 23Na MR imaging. Radiology. 2003; 227:529-537.
6. Weber MA, Zoubaa S, Schlieter M, et al. Diagnostic performance of spectroscopic and perfusion MRI for distinction of brain tumors. Neurology. 2006;66:1899-1906.
7. Stieltjes B, Schlüter M, Didinger B, et al. Diffusion tensor imaging in primary brain tumors: reproducible quantitative analysis of corpus callosum infiltration and contralateral involvement using a probabilistic mixture model. Neuroimage. 2006;31:531-542.
8. Chen W, Cloughesy T, Kamdar N, et al. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. J Nucl Med. 2005;46:945-952.
9. Minn H. PET and SPECT in low-grade glioma. Eur J Radiol. 2005;56:171-178.
10. Seiz M, Dimitrakopoulou-Strauss A, Schubert GA, et al. Differentiation between malignant transformation and tumour recurrence by (68)Ga-bombesin and (18)F-FDG-PET in patients with low grade gliomas. Hell J Nucl Med. 2008;11:149-152.
11. Cha S, Knopp EA, Johnson G, et al. Intracranial mass lesions: dynamic contrast-enhanced susceptibility-weighted echo-planar perfusion MR imaging. Radiology. 2002;223:11-29.
12. Choyke PL, Dwyer AJ, Knopp MV. Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging. J Magn Reson Imaging. 2003;17:509-520.
13. Law M. MR spectroscopy of brain tumors. Top Magn Reson Imaging. 2004;15:291-313.
14. Knopp EA, Cha S, Johnson G, et al. Glial neoplasms: dynamic contrastenhanced T2*-weighted MR imaging. Radiology. 1999;211:791-798.
15. Barbier EL, Lamalle L, Decorps M. Methodology of brain perfusion imaging. J Magn Reson Imaging. 2001;13:496-520.
16. Warmuth C, Günther M, Zimmer C. Quantification of blood flow in brain tumors: comparison of arterial spin labeling and dynamic susceptibilityweighted contrast-enhanced MR imaging. Radiology. 2003;228:523--532.
17. Lin A, Bluml S, Mamelak AN. Efficacy of proton magnetic resonance spectroscopy in clinical decision making for patients with suspected malignant brain tumors. J Neurooncol. 1999;45:69-81.
18. Schlemmer HP, Bachert P, Herfarth KK, et al. Proton MR spectroscopic evaluation of suspicious brain lesions after stereotactic radiotherapy. Am J Neuroradiol. 2001;22:1316-1324.
19. Guo AC, Cummings TJ, Dash RC, et al. Lymphomas and high-grade astrocytomas: comparison of water diffusibility and histologic characteristics. Radiology. 2002;224:177-183.
20. Provenzale JM, Mukundan S, Barboriak DP. Diffusion-weighted and perfusion MR imaging for brain tumor characterization and assessment of treatment response. Radiology. 2006;239:632-649.
21. Nielles-Vallespin S, Weber MA, Bock M, et al. 3D radial projection technique with ultrashort echo times for sodium MRI: clinical applications in human brain and skeletal muscle. Magn Reson Med. 2007;57:74-81.
22. Ouwerkerk R, Morgan RH. 23Na MRI: from research to clinical use. J Am Coll Radiol. 2007;4:739-741.
23. Goldman S, Levivier M, Pirotte B, et al. Regional glucose metabolism and histopathology of gliomas. A study based on positron emission tomographyguided stereotactic biopsy. Cancer. 1996;78:1098-1106.
24. Delbeke D, Meyerowitz C, Lapidus RL, et al. Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from highgrade brain tumors with PET. Radiology. 1995;195:47-52.
25. Mier W, Haberkorn U, Eisenhut M. [18F]FLT: portrait of a proliferation marker. Eur J Nucl Med. 2002;29:165-169.
26. Hatakeyama T, Kawai N, Nishiyama Y, et al. 11C-methionine (MET) and 18F-fluorothymidine (FLT) PET in patients with newly diagnosed glioma. Eur J Nucl Med Mol Imaging. 2008;35:2009 -2017.
27. Lev MH, Ozsunar Y, Henson JW, et al. Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendroglimoas. Am J Neuroradiol. 2004;25:214-221.
28. Calvar JA, Meli FJ, Romero C, et al. Characterization of brain tumors by MRS, DWI and Ki-67 labeling index. J Neurooncol. 2005;72:273-280.
29. Walker C, du Plessis DG, Fildes D, et al. Correlation of molecular genetics with molecular and morphological imaging in gliomas with an oligodendroglial component. Clin Cancer Res. 2004;10:7182-7191.
30. Jackson J, Meyer C, Nishimura D, et al. Selection of a convolution function for Fourier inversion using gridding. IEEE Trans Med Imaging. 1991;10: 473-478.
31. Weber MA, Viehoever A, Stieltjes B, et al. Intracerebral manifestation of an atypical monoclonal plasma cell hyperplasia depicte d by magnetic resonance perfusion and diffusion tensor imaging as well as magnetic resonance spectroscopy. Am J Roentgenol. 2005;185:784-787.
32. Sijens PE, van den Bent MJ, Nowak PJ, et al. 1H chemical shift imaging reveals loss of brain tumor choline signal after administration of Gd-contrast. Magn Reson Med. 1997;37:222-225.
33. Law M, Cha S, Knopp EA, et al. High-grade gliomas and solitary metastases: differentiation by using perfusion and proton spectroscopic MR imaging. Radiology. 2002;222:715-721.
34. Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. Am J Neuroradiol. 2003; 24:1989-1998.
35. Möller-Hartmann W, Herminghaus S, Krings T, et al. Clinical application of proton magnetic resonance spectroscopy in the dia gnosis of intracranial masslesions. Neuroradiology. 2002;44:371-381.
36. Luh WM, Wong EC, Bandettini PA, et al. QUIPPS II with thin-slice TI1 periodic saturation: a method for improving accuracy of quantitative perfusion imaging using pulsed arterial spin labeling. Magn Reson Med. 1999;41: 1246-1254.
37. Wong EC, Buxton RB, Frank LR. Quantitative imaging of perfusion using a single subtraction (QUIPSS and QUIPSS II). Magn Reson Med. 1998;39: 702-708.
38. Kim SG. Quantification of relative cerebral blood flow change by flowsensitive alternating inversion recovery (FAIR) technique: application to functional mapping. Magn Reson Med. 1995;34:293-301.
39. Buxton RB, Frank LR, Wong EC, et al. A general kinetic model for quantitative perfusion imaging with arterial spin labeling. Magn Reson Med. 1998;40:383-396.
40. Weber MA, Thilmann C, Lichy MP, et al. Assessment of irradiated brain metastases by means of arterial spin-labeling and dynamic susceptibilityweighted contrast-enhanced perfusion MRI: initial results. Invest Radiol. 2004;39:277-287.
41. Hartmann M, Heiland S, Harting I, et al. Distinguishing of primary cerebral lymphoma from high-grade glioma with perfusion-weighted magnetic resonance imaging. Neurosci Lett. 2003;338:119-122.
42. Wetzel SG, Cha S, Johnson G, et al. Relative cerebral blood volume measurements in intracranial mass lesions: interobserver and intraobserver reproducibility study. Radiology. 2002;224:797-803.
43. Menda Y, Boles Ponto LL, Dornfeld KJ, et al. Kinetic analysis of 3′-deoxy- 3′-18F-fluorothymidine (18F-FLT) in head and neck cancer patients before and early after initiation of chemoradiation therapy. J Nucl Med. 2009;50: 1028-1035.
44. Murakami R, Hirai T, Sugahara T, et al. Grading astrocytic tumors by using apparent diffusion coefficient parameters: superiority of a one- versus twoparameter pilot method. Radiology. 2009;251:838-845.
45. Arvinda HR, Kesavadas C, Sarma PS, et al. Glioma grading: sensitivity, specificity, positive and negative predictive values of diffusion and perfusion imaging. J Neurooncol. 2009;94:87-96.
46. Jonckheere AR. A distribution-free k-sample test against ordered alternatives. Biometrica. 1954;41:133-145.
47. Catalaa I, Henry R, Dillon WP, et al. Perfusion, diffusion and spectroscopy values in newly diagnosed cerebral gliomas. NMR Biomed. 2006;19:463-475.
48. Dowling C, Bollen AW, Noworolski SM, et al. Preoperative proton MR spectroscopic imaging of brain tumors: correlation with histopathologic analysis of resection specimens. Am J Neuroradiol. 2001;22:604-612.
49. Stadlbauer A, Nimsky C, Buslei R, et al. Proton magnetic resonance spec-troscopic imaging in the border zone of gliomas: correlation of metabolic and histological changes at low tumor infiltration-initial results. Invest Radiol. 2007;42:218-223.
50. Christoforidis GA, Yang M, Kontzialis MS, et al. High resolution ultra high field magnetic resonance imaging of glioma microvascularity and hypoxia using ultra-small particles of iron oxide. Invest Radiol. 2009;44: 375-383.
51. Wintersperger BJ, Runge VM, Tweedle MF, et al. Brain tumor enhancement in magnetic resonance imaging: dependency on the level of protein binding of applied contrast agents. Invest Radiol. 2009;44:89-94.
52. Aronen HJ, Gazit IE, Louis DN, et al. Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. Radiology. 1994;191:41-51.
53. Sugahara T, Korogi Y, Kochi M, et al. Correlation of MR imagingdetermined cerebral blood volume maps with histologic and angiographic determination of vascularity of gliomas. Am J Roentgenol. 1998;171: 1479-1486.
54. Shin JH, Lee HK, Kwun BD, et al. Using relative cerebral blood flow and volume to evaluate the histopathologic grade of cerebral gliomas: preliminary results. Am J Roentgenol. 2002;179:783-789.
55. + influx is required for volume loss during programmed cell death. J Biol Chem. 2003;278:39176-39184.
56. Thulborn KR, Davis D, Adams H, et al. Quantitative tissue sodium concentration mapping of the growth of focal cerebral tumors with sodium magnetic resonance imaging. Magn Reson Med. 1999;41:351-359.
57. Floeth FW, Pauleit D, Wittsack HJ, et al. Multimodal metabolic imaging of cerebral gliomas: positron emission tomography with [18F] fluoroethyl-Ltyrosine and magnetic resonance spectroscopy. J Neurosurg. 2005;102:318-327.